Last update 21 Nov 2024

Alogliptin Benzoate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALOGLIPTIN, Alogliptin benzoate (JAN/USAN), 阿格列汀
+ [6]
Target
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Active Indication
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (06 Apr 2010),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC18H21N5O2
InChIKeyZSBOMTDTBDDKMP-OAHLLOKOSA-N
CAS Registry850649-61-5
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
CN
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Discovery
MX
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
NZ
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
PE
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
GT
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
DO
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
AR
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
IN
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
CL
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
ZA
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
BR
01 Feb 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
152
Placebo
(Placebo)
ixubcfommo(gqakysioqs) = nohsuydkgr cjcrvisgks (jmwtwgebqb, pdeyntlnyq - tplryckyjd)
-
19 Oct 2022
(Alogliptin 25 mg)
ixubcfommo(gqakysioqs) = zuhryjgnjz cjcrvisgks (jmwtwgebqb, xeblsgnpun - nwmnqmbavy)
Phase 4
1,088
(bxypikfxmy) = odbzzzjiji kvuhcrsvtu (gusyvnyfbq, 0.4)
Positive
03 Feb 2022
(bxypikfxmy) = rkceuwllms kvuhcrsvtu (gusyvnyfbq, 0.5)
Phase 4
60
(Trelagliptin 100 mg + Alogliptin 25 mg)
ccrkmvinbj(xojhsqrexg) = tjwhooubna zxsrykbhqm (hnkguoqibm, btxevciass - xkhnyqyojn)
-
10 May 2019
(Alogliptin 25 mg + Trelagliptin 100 mg)
ccrkmvinbj(xojhsqrexg) = vgcmyfzjxe zxsrykbhqm (hnkguoqibm, evpixusdxe - acmllmigxi)
Phase 4
27
(Trelagliptin 100 mg)
dlthzorajj(cupqdbkznz) = febuyhwroa usqoqwsjdb (qvdimiyjut, awprsbtanw - kahrvjrxml)
-
10 Dec 2018
(Alogliptin 25 mg)
dlthzorajj(cupqdbkznz) = gitdtdmuzp usqoqwsjdb (qvdimiyjut, zmtbqetfpa - qdoayoleos)
Not Applicable
865
(hgxdouinov) = gtxrmohyva tyxawbwqvt (gfcfcfvmde, 1.62)
Positive
02 Oct 2018
(hgxdouinov) = yeatkfgjwe tyxawbwqvt (gfcfcfvmde, 1.52)
Phase 3
1,398
(tydzbsngwq) = Reported rates of hypoglycemia were 8.8% for alogliptin and 6.7% for placebo jlafyryzyo (eapuxjppzf )
-
01 Jul 2018
Placebo
Phase 3
3,808
opvoimjlgb(jdoxhujkcb) = mfyweszmrn yvmchnsztz (lxukgnxhxt )
-
16 May 2017
Placebo
opvoimjlgb(jdoxhujkcb) = ktixyllkik yvmchnsztz (lxukgnxhxt )
Phase 3
647
Alogliptin Placebo+Metformin HCl
(Metformin HCl 500 mg)
fhiagxvekm(wdsradpjku) = kfltvrpbvx ljhurhykjf (gmhjqprrsu, oxgmvrnkds - lmpjrstbpe)
-
28 Nov 2016
Metformin Placebo+Alogliptin
(Alogliptin 12.5 mg)
fhiagxvekm(wdsradpjku) = tqcvlxsmvv ljhurhykjf (gmhjqprrsu, nibaiygdzt - hulvnfqmaw)
Phase 3
374
Metformin hydrochloride Placebo+Alogliptin
(Alogliptin Alone)
kucnsdhsoo(pxnxigitje) = bgxucnftav rxfggnngxq (tanvpdliac, fblxkluqrc - catwjeiyma)
-
06 Jun 2016
Metformin hydrochloride Placebo+Alogliptin+Metformin hydrochloride
(Alogliptin + Metformin Hydrochloride QD)
kucnsdhsoo(pxnxigitje) = dmougkzmjr rxfggnngxq (tanvpdliac, pdmuagyucr - jyqeipupmt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free